David B. Goldstein
Professor
bio  •  lab members  •  lab website

Representative Publications:

• Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med. (2003) Feb 6;348(6):553-6.

• Weale ME, Depondt C, Macdonald SJ, Smith A, Lai PS, Shorvon, SD, Wood NW, Goldstein DB. Selection and evaluation of tagging SNPs in the neuronal sodium channel gene SCN1A: Implications for linkage disequilibrium gene mapping. Am J Hum Genet. (2003) Sep;73(3):551-65.

• Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nature Reviews Genetics (2003) 4:937- 947.

• Soranzo N, Cavalleri GL, Weale ME, Wood NW, Depondt C, Marguerie R, Sisodiya SM, Goldstein DB. Identifying candidate causal variants responsible for altered activity of the ABCB1 multi-drug resistance gene. Genome Research (2004) 14:1333-1344.

• Goldstein, DB and Hirschhorn, J. In genetic control of disease, does “race” matter? Nature Genetics (2004) 36: 1243-1244.

• Ahmadi K, Weale M, Zhengyu X, Soranzo N, Yarnall D, Briley J, Maruyama Y, Kobayashi M, Wood N, Spurr N, Burns D, Roses A, Saunders A & Goldstein DB. A single nucleotide polymorphism tagging set for human drug metabolism and transport. Nature Genetics (2005) 37:84-89.

• Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB. Genetic predictors of maximum tolerated dose of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci (2005) 102(15):5507-12.

• Cavalleri G., Lynch J, Depondt C, Burley M, Wood N, Sisodiya S, Goldstein DB. Failure to replicate previous associations with sporadic temporal lobe epilepsy: where to from here? Brain, in press.